PharmaShots | Incisive News in 3 Shots

Subscribe Now

IDH1 mutation

$Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation$

Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelod...

December 16, 2019

Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

Agios Pharmaceuticals' Tibsovo (ivosidenib) Receives Approval For R/R Acute Myeloid Leukemia (AML) and IDH1 Mutation

June 26, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us